Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model

Clinical Cancer Research

Volumn 12, Issue 19, 2006, Pages 5859-5868

  Lee, Young Sook ^a,b   Kim, Joo Hang ^a,b   Choi, Kyung Ju ^a,b   Choi, Il Kyu ^a,b   Kim, Hoguen ^a   Cho, Sungae ^a   Cho, Byoung Chul ^b   Yun, Chae Ok ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL POPULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD80; DRUG THERAPY, COMBINATION; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 33750332951     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0935     Document Type: Article

References (39)

1. Oosterhoff D, van Beusechem VW. Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy. J Exp Ther Oncol 2004;4:37-57.
2. Nishimura T, Watanabe K, Lee U, et al. Systemic in vivo antitumor activity of interleukin-12 against both transplantable and primary tumor. Immunol Lett 1995;48:149-52.
3. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
4. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19:641-4.
5. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-403.
6. Zitvogel L, Lotze MT. Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. Res Immunol 1995;146:628-38.
7. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466-74.
8. Lui VW, He Y, Falo L, et al. Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther 2002;13:177-85.
9. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of 67 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-32.
10. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of c DNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991;146:3074-81.
11. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212,
12. Hathcock KS, Laszlo G, Pucillo C, et al. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994;180:631-40
13. Chamberlain RS, Carroll MW, Bronte V, et al. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 1996;56:2832-6.
14. Tatsumi T, Takehara T, Kanto T, et al. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma. Hepatology 1999;30:422-9
15. Morioka J, Kajiwara K, Yoshikawa K, et al. Vaccine therapy for murine glioma using tumor cells genetically modified to express B7.1. Neurosurgery 2004;54:182-9; discussion 189-90.
16. Guckel B, Meyer GC, Rudy W, et al. Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma. Cancer Gene Ther 1999;6:228-37.
17. Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994;180:211-22.
18. Putzer BM, Hitt M, Muller WJ, et al. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci U S A 1997;94:10889-94
19. Zitvogel L, Robbins PD, Storkus WJ, et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996;26:1335-41.
20. Murphy EE, Terres G, Macatonia SE, et al. B7 and interleukin 12 cooperate for proliferation and interferon a production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994;180:223-31.
21. Kim J, Cho JY, Kim JH, et al. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther 2002;9:725-36.
22. Yun CO, Kim E, Koo T, et al. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 2005;12:61-71.
23. Musiani P, Modesti A, Giovarelli M, et al. Cytokines, tumour-cell death, and immunogenicity: a question of choice. Immunol Today 1997;18:32-6.
24. Brunda MJ, Gately MK. Antitumor activity of interleukin-12. Clin Immunol Immunopathol 1994;71:253-5.
25. Schmidt-Wolf G, Schmidt-Wolf IG. Cytokines and clinical gene therapy. Eur J Immunol 1995;25:1137-40.
26. Schmidt-Wolf GD, Schmidt-Wolf IG. Cytokines and gene therapy. Immunol Today 1995;16:173-5.
27. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells 1994;12:154-68.
28. Gately MK, Brunda MJ. Interleukin-12: a pivotal regulator of cell-mediated immunity. Cancer Treat Res 1995;80:341-66.
29. Wu TC, Huang AY, Jaffee EM, et al. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-21.
30. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
31. Mazzolini G, Qian C, Xie X, et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther 1999;6:514-22.
32. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol 1994;6:157-67.
33. + T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A 1993;90:10188-92.
34. Manetti R, Gerosa F, Giudizi MG, et al. Interleukin 12 induces stable priming for interferon γ (IFN-γ) production during differentiation of human T helper (Th) cells and transient IFN-γ production in established Th2 cell clones. J Exp Med 1994;179:1273-83.
35. Coughlin CM, Salhany KE, Gee MS, et al. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25-34.
36. Barajas M, Mazzolini G, Genove G, et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001;33:52-61.
37. Putzer BM, Rodicker F, Hitt MM, et al. Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model. Mol Ther 2002;5:405-12.
38. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997;90:2541-8.
39. Chen L, Chen D, Block E, et al. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 1997;159:351-9.